{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:58:24Z","timestamp":1790355504719,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory\/resistant circumstances. Much of the published data for its use in pediatric blood disorders has been in post-transplant autoimmune cytopenias. Here we describe three patients in whom daratumumab was used outside of post-transplant autoimmune cytopenias, highlighting further potential uses of this medication.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1055473","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T05:25:13Z","timestamp":1669699513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Maria A.","family":"Pereda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Hosahalli Vasanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amma","family":"Owusu-Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari H.","family":"Dallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Pateva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.02722","article-title":"CD38: A target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/PBC.28591","article-title":"Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects","volume":"67","author":"Koo","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2019.12.025","article-title":"Anti-CD20-mediated b-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/S40348-021-00114-Y","article-title":"Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature","volume":"8","author":"Driouk","year":"2021","journal-title":"Mol Cell Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16171","article-title":"Post-allogeneic transplant Evans syndrome successfully treated with daratumumab","volume":"187","author":"Blennerhassett","year":"2019","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/PBC.28010","article-title":"Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia","volume":"67","author":"Even-Or","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/S00277-020-04063-W","article-title":"Daratumumab for refractory warm autoimmune hemolytic anemia","volume":"100","author":"Jain","year":"2021","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/TRF.15539","article-title":"Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient","volume":"59","author":"Cooling","year":"2019","journal-title":"Transfusion (Paris)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3324\/HAEMATOL.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018121254\/-\/DCSUPPLEMENTAL","article-title":"Daratumumab in sensitized kidney transplantation: Potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.667515","article-title":"Case report: Resetting the humoral immune response by targeting plasma cells with daratumumab in anti-phospholipid syndrome","volume":"12","author":"Pleguezuelo","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/S13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.02134","article-title":"CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/BLOOD.2021015220","article-title":"Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma","volume":"140","author":"Yamamoto","year":"2022","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.624661","article-title":"Daratumumab for the management of newly diagnosed and Relapsed\/Refractory multiple myeloma: Current and emerging treatments","volume":"10","author":"Offidani","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/TRF.16425","article-title":"Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens","volume":"61","author":"Phou","year":"2021","journal-title":"Transfusion (Paris)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2450\/2020.0004-20","article-title":"New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing","volume":"18","author":"Izaguirre","year":"2020","journal-title":"Blood Transfus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/TRF.16687","article-title":"Antibody incidence and red blood cell transfusions in patients on daratumumab","volume":"61","author":"Tauscher","year":"2021","journal-title":"Transfusion (Paris)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/HEMATOLOGY.2021000306","article-title":"How to avoid the problem of erythrocyte alloimmunization in sickle cell disease","volume":"2021","author":"Pirenne","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/J.ECLINM.2020.100432","article-title":"The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study","volume":"24","author":"Nickel","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2011-05-355263","article-title":"Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation","volume":"118","author":"Cutler","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2009-09-244525","article-title":"The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure","volume":"115","author":"Spellman","year":"2010","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S190327","article-title":"Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives","volume":"10","author":"Barcellini","year":"2019","journal-title":"J Blood Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.17565","article-title":"Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series","volume":"194","author":"Khandelwal","year":"2021","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/PBC.29290","article-title":"Targeting plasma cells with daratumumab aids in the treatment of post-transplant autoimmune-like hepatitis","volume":"68","author":"Epperly","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/BMT.2014.331","article-title":"Donor HLA-specific abs: to BMT or not to BMT","volume":"50","author":"Leffell","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0072141","article-title":"The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children","volume":"8","author":"Ansari","year":"2013","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBMT.2011.04.013","article-title":"Anti-HLA antibodies in double umbilical cord blood transplantation","volume":"17","author":"Brunstein","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2009-10-249219","article-title":"The impact of anti-HLA antibodies on unrelated cord blood transplantations","volume":"116","author":"Takanashi","year":"2010","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000503951","article-title":"Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/S00467-020-04811-0","article-title":"A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome","volume":"36","author":"Dossier","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2021.279851","article-title":"Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. a retrospective observational campus ALL study","volume":"107","author":"Cerrano","year":"2022","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.575168","article-title":"Real world experience of daratumumab: Evaluating lymphopenia and adverse events in multiple myeloma patients","volume":"10","author":"Cottini","year":"2021","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/BLOOD-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: A single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1055473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T05:25:16Z","timestamp":1669699516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1055473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2022.1055473"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1055473","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1055473"}}